Prevalence and factors of COVID-19 vaccine refusal among solid cancer patients in China: an application of the health belief model

Abstract

IntroductionIt is essential to protect cancer patients from contracting COVID-19 through vaccination. A majority of cancer patients are recommended by international health authorities to take up the vaccines. COVID-19 vaccine refusal among cancer patients during the pandemic period is under-researched. This study investigated factors of vaccine refusal based on the Health Belief Model (HBM).MethodsA cross-sectional study was conducted among female breast cancer patients, male/female thyroid cancer patients, and gynecological cancer patients in Shantou, China from April to August 2022 (n = 1,115). Multinomial logistic regression analysis adjusted for socio-demographics was conducted to test factors of COVID-19. Adjusted odds ratios of the two models comparing vaccine refusal vs. “vaccine non-refusal” and vaccine refusal vs. ever-vaccination were derived and presented.ResultsOf all the participants, the prevalence of vaccine refusal, “vaccine non-refusal,” and ever-vaccination was 25.9, 22.2, and 51.8%, respectively. In both multinomial logistic regression models, significant factors of vaccine refusal included socio-demographics (age, education level, employment status, monthly household income, cancer type, duration since cancer diagnosis, current treatment status) and some vaccine-related HBM (perceived benefits, perceived barriers, cue to action, and self-efficacy). Perceived severity of COVID-19 was significant only in the vaccine refusal vs. ever-vaccination model. In neither model, perceived susceptibility to contract COVID-19 was statistically significant.ConclusionAbout ¼ of the participants expressed vaccine refusal. Interventions are warranted. Future longitudinal studies are needed to verify this study’s findings. Pilot interventions should also be launched to test effectiveness of interventions modifying the significant HBM factors found in this study.

Outcomes of COVID‐19 in patients with lymphomas participating in registered clinical trials: A real‐world study from China in the Omicron outbreak era

“…Vaccines of COVID‐19 have been proven to be safe and effective for preventing infection or attenuating disease severity and are also recommended to cancer patients. However, the concerns of vaccines included cancer progression, potential long‐term toxicity, or interfere with treatment resulted in a low acceptance of the vaccine in cancer patients in China 29–31 . In our study, only 34.5% of patients were vaccinated against COVID‐19 and 10% of patients had received the third dose of vaccines.…”

“…However, the concerns of vaccines included cancer progression, potential long-term toxicity, or interfere with treatment resulted in a low acceptance of the vaccine in cancer patients in China. [29][30][31] In our study, only 34.5% of patients were vaccinated against COVID-19 and 10% of patients had received the third dose of vaccines. The lower vaccine serologic response was reported in HM patients, particularly those with lymphoid cancers and/or receiving anti-CD20 therapy with impaired immune function [32][33][34][35] ; thus, the protective effect of vaccine might be limited in these patients.…”

Long-Term Immunological Alertness and Response to COVID-19 Vaccination—Conditions for Prevention in Early Palliative Oncological Care Patients

“…It is currently recommended that cancer patients be vaccinated in a regular manner [ 18 , 46 , 47 ]. The common acceptance of the COVID-19 vaccine is not universal, and several reports have described situations where people strongly refuse to be vaccinated [ 48 , 49 ]. A similar situation may also arise in cancer patients under or after treatment.…”